遠大醫藥(00512.HK)2024年淨利24.68億港元 同比增長約31.3%
格隆匯3月12日丨遠大醫藥(00512.HK)公告,截至2024年12月31日止年度的收益約港幣116.4億元,同比增長約10.6%。公司擁有人應佔期內溢利約爲港幣24.68億元,較同期相比上漲約31.3%。如撇除人民幣與港元匯率變動的影響,即較2023年同期相比上漲約34.0%。集團基於良好的業績表現,以爲推動全體股東共用公司經營發展成果,切實保護股東利益爲目標,今年董事會建議派發2024年年度末期股息每股0.26港元,共約港幣910,470,000元。
截至2024年12月31日止,集團繼續投入資源用於在研項目的推進及創新項目的引進,研發費用加上資本化研發支出、新項目的預付款及其他投入,集團於研發工作及項目的投入約港幣22.7億元。
集團核藥抗腫瘤診療板塊錄得收益約港幣5.89億元,較2023年同期(約港幣2.17億元)比較上漲約176.6%(撇除人民幣與港元匯率變動的影響),核心產品易甘泰釔[90Y]微球注射液已進入快速放量期。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.